Intracranial delivery of high-dose radiation treatment with stereotactic techniques has paved the way for treatment of extracranial sites.
Methods
The authors review the evolution of stereotactic body radiation therapy (SBRT) and its application to tumors in the lung and abdomen, addressing both the technical concerns associated with treatment delivery and the emerging clinical data.
Results
Radiation delivery systems have overcome the obstacles with immobilization, respiration, visualization, and daily reproducible imaging. Lung SBRT has been associated with local control rates of over 90%, and liver SBRT has ranged from 55% to 93%. SBRT is being explored in other sites such as the pancreas and kidney. Mature data from ongoing trials will be available in the next 5 years.
Conclusions
Modern stereotactic radiation treatment techniques allow the safe delivery of high doses to extracranial sites with minimal toxicity, which results in improved outcomes.
References
1.
LeksellL.. The stereotaxic method and radiosurgery of the brain.Acta Chir Scand.1951; 102: 316–319.
2.
LeksellL.. Stereotaxis and Radiosurgery.Springfield, IL: Charles C. Thomas; 1971.
3.
KondziolkaD., MaitzA.H., NiranjanA.. An evaluation of the Model C gamma knife with automatic patient positioning.Neurosurgery.2002; 50: 429–431; discussion 431-432.
WulfJ., HädingerU., OppitzU.. Stereotactic radiotherapy of extracranial targets: CT-simulation and accuracy of treatment in the stereotactic body frame.Radiother Oncol.2000; 57: 225–236.
6.
UematsuM., ShiodaA., SudaA.. Computed tomography-guided frameless stereotactic radiotherapy for stage I non-small cell lung cancer: a 5-year experience.Int J Radiat Oncol Biol Phys.2001; 51: 666–670.
7.
OnishiH., ShiratoH., NagataY.. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study.J Thorac Oncol.2007; 2(7 suppl 3): S94–S100.
8.
NagataY., TakayamaK., MatsuoY.. Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame.Int J Radiat Oncol Biol Phys.2005; 63: 1427–1431. Epub 2005 Sep 19.
9.
TimmermanR., McGarryR., YiannoutsosC.. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer.J Clin Oncol.2006; 24: 4833–4839.
10.
BaumannP., NymanJ., LaxI.. Factors important for efficacy of stereotactic body radiotherapy of medically inoperable stage I lung cancer. a retrospective analysis of patients treated in the Nordic countries.Acta Oncol.2006; 45: 787–795.
11.
ZimmermannF.B., GeinitzH., SchillS.. Stereotactic hypofractionated radiation therapy for stage I non-small cell lung cancer.Lung Cancer.2005; 48: 107–114. Epub 2004 Dec 19.
12.
McGarryR.C., PapiezL., WilliamsM.. Stereotactic body radiation therapy of early-stage non-small-cell lung carincoma: phase I study.Int J Radiat Oncol Biol Phys.2005; 63: 1010–1015. Epub 2005 Aug 22.
13.
XiaT., LiH., SunQ.. Promising clinical outcome of stereotactic body radiation therapy for patients with inoperable stage I/II non-small-cell lung cancer.Int J Radiat Oncol Biol Phys.2006; 66: 117–125.
SelznerM., MorseM.A., VredenburghJ.J.. Liver metastases from breast cancer: long term survival after curative resection.Surgery.2000; 127: 383–389.
20.
LeibelS.A., PajakT.F., MassulloV.. A comparison of misonidazole sensitized radiation therapy to radiation therapy alone for the palliation of hepatic metastases: results of a Radiation Therapy Oncology Group randomized prospective trial.Int J Radiat Oncol Biol Phys.1987; 13: 1057–1064.
21.
MohiuddinM., ChenE., AhmadN.. Combined liver radiation and chemotherapy for palliation of hepatic metastases from colorectal cancer.J Clin Oncol.1996; 14: 722–728.
22.
RobertsonJ.M., LawrenceT.S., WalkerS.. The treatment of colorectal liver metastasis with conformal radiation therapy and regional chemotherapy.Int J Radiat Oncol Biol Phys.1995; 32: 445–450.
23.
JacksonA., Ten HakenR.K., RobertsonJ.M.. Analysis of clinical complication data for radiation hepatitis using a parallel architecture model.Int J Radiat Oncol Biol Phys.1995; 31: 883–891.
24.
DawsonL.A., NormolleD., BalterJ.M.. Analysis of radiation-induced liver disease using the Lyman NTCP model.Int J Radiat Oncol Biol Phys.2002; 53: 810–821.
25.
LaxI., BlomgrenH., NäslundI.. Stereotactic radiotherapy of malignancies in the abdomen. methodological aspects.Acta Oncol.1994; 33: 677–683.
26.
BlomgrenH., LaxI., NäslundI.. Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. clinical experience of the first thirty-one patients.Acta Oncol.1995; 34: 861–870.
27.
HerfarthK.K., DebusJ., LohrF.. Stereotactic single-dose radiation therapy of liver tumors: results of a phase I/II trial.J Clin Oncol.2001; 19: 164–170.
28.
LieskovskyY.C., KoongA., FisherG.. Phase I Dose Escalation Study of Cyberknife Stereotactic Radiosurgery for Liver Malignancies. In: Proceedings from the 47th Annual American Society for Therapeutic Radiology and Oncology Meeting; October 16-20, 2005; Denver, CO. Abstract 2089.
29.
SchefterT.E., KavanaghB.D., TimmermanR.D.. A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases.Int J Radiat Oncol Biol Phys.2005; 62: 1371–1378.
30.
KavanaghB.D., SchefterT.E., CardenesH.R.. Interim analysis of a prospective phase I/II trial of SBRT for liver metastases.Acta Oncol.2006; 45: 848–855.
31.
KatzA.W., Carey-SampsonM., MuhsA.G.. Hypofractionated stereotactic body radiation therapy (SBRT) for limited hepatic metastases.Int J Radiat Oncol Biol Phys.2007; 67: 793–798. Epub 2006 Dec 29.
32.
DawsonL.A., EcclesC., CraigT.. Individualized image guided iso-NTCP based liver cancer SBRT.Acta Oncol.2006; 45: 856–864.
33.
SchefterT.E., CardenesH.R., KavanaghB.D.. Normal tissue dose constraints in stereotactic body radiation therapy for liver tumors. In: KavanaghB.D., TimmermanR.D., eds. Stereotactic Body Radiation Therapy.Baltimore, MD: Lippincott, Williams, and Wilkins; 2005: 115–127.
34.
SeongJ., ParkH.C., HanK.H.. Clinical results and prognostic factors in radiotherapy for unresectable hepatocellular carcinoma: a retrospective study of 158 patients.Int J Radiat Oncol Biol Phys.2003; 55: 329–336.
35.
MornexF., GirardN., BeziatC.. Feasibility and efficacy of highdose three-dimensional-conformal radiotherapy in cirrhotic patients with small-size hepatocellular carcinoma non-eligible for curative therapies: mature results of the French Phase II RTF-1 Trial.Int J Radiat Oncol Biol Phys.2006; 66: 1152–1158.
36.
Méndez RomeroA., WunderinkW., HussainS.M.. Stereotactic body radiation therapy for primary and metastatic liver tumors: a single institution phase I/II study.Acta Oncol.2006; 45: 831–837.
37.
ChoiB.O., JangH.S., KangK.M.. Fractionated stereotactic radiotherapy in patients with primary hepatocellular carcinoma.Jpn J Clin Oncol.2006; 36: 154–158.
38.
TseR.V., HawkinsM., LockwoodG.. Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma.J Clin Oncol.2008; 26(4): 657–664. Epub 2008 Jan 2.
39.
MoertelC.G., FrytakS., HahnR.G.. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil. The Gastrointestinal Tumor Study Group.Cancer.1981; 48: 1705–1710.
40.
RoldanG.E., GundersonL.L., NagorneyD.M.. External beam versus intraoperative and external beam irradiation for locally advanced pancreatic cancer.Cancer.1988; 61: 1110–1116.
41.
RabenA., MychalczakB., BrennanM.F.. Feasibility study of the treatment of primary unresectable carcinoma of the pancreas with 103Pd brachytherapy.Int J Radiat Biol Onc Phys.1996; 35: 351–356.
42.
HoyerM., RoedH., SengelovL.. Phase-II study on stereotactic raditotherapy of locally advanced pancreatic carcinoma.Radiother Oncol.2005; 76: 48–53.
43.
KoongA.C., LeQ.T., HoA.. Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer.Int J Radiat Oncol Biol Phys.2004; 58: 1017–1021.
44.
KoongA.C., ChristoffersonE., LeQ.T.. Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer.Int J Radiat Oncol Biol Phys.2005; 63: 320–323.
45.
SvedmanC., SandströmP., PisaP.. A prospective phase II trial of using extracranial stereotactic radiotherapy in primary and metastatic renal cell carcinoma.Acta Oncol.2006; 45: 870–875.
